Here, we propose that the antineoplastic efficacy of CDK inhibitors like palbociclib and ribociclib in the treatment of MYCN-amplified neuroblastoma may require some level of expression of the wt RB protein and that testing the expression of that in patients’ tumor samples at the stage of diagnosis may be of some help in designing more precise therapeutic protocols. This evidence concerns the gene RB1 and neuroblastoma.